Results 231 to 240 of about 40,241 (253)

Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)

Expert Opinion on Biological Therapy, 2023
Purpose To assess the awareness of biosimilar intravitreal anti-VEGF agents among retina specialists practicing in the United States (US) and Europe. Methods A 16-question online survey was created in English and distributed between Dec 01, 2021 and Jan ...
Ashish Sharma, F. Holz, C. Regillo, Bailey Freund, D. Sarraf, A. Khanani, C. Baumal, N. Holekamp, R. Tadayoni, Nilesh Kumar, N. Parachuri, B. Kuppermann, International Retina, Biosimilar Study Group Inter Bios Group, F. Bandello, G. Querques, Anat Loewenstein, Şengül Özdek, K. Rezai, Kodjikian Laurent, Alper Bilgic, P. Lanzetta, Dinah Zur, Nicolas Yannuzzi, G. Corradetti, Peter Kaiser, A. Hilely, David Boyer, Aleksandra Rachitskaya, U. Chakravarthy, Maximilian W. M. Wintergerst, Valentina Sarao, Barbara Parolini, P. Mruthyunjaya, Quan Dong, Diana Nguyen, Pearse A Do, Tarek Keane, Jayanth Hassan, David Sridhar, Dilraj Eichenbaum, Martin Grewal, Splitzer   +42 more
semanticscholar   +1 more source

Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.

JAMA dermatology, 2023
Importance Biosimilars have the potential to reduce costs for the management of moderate-to-severe psoriasis compared with originators. However, the extrapolation of evidence enables the approval of a biosimilar for use in indications held by the ...
D. B. Phan, S. Elyoussfi, Michael Stevenson, M. Lunt, R. Warren, Zenas Z N Yiu   +5 more
semanticscholar   +1 more source

Projected US savings from biosimilars, 2021-2025.

American Journal of Managed Care, 2022
OBJECTIVES Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain.
Andrew W Mulcahy, Christine Buttorff, K. Finegold, Zeid El-Kilani, Jon F Oliver, Stephen Murphy, Amber Jessup   +6 more
semanticscholar   +1 more source

Biosimilars

International Journal of Nutrition, Pharmacology, Neurological Diseases, 2021
Biologics are medicines primarily derived from living systems and produced through recombinant DNA (rDNA) and monoclonal technologies. Generic version of biologics with improved efficacy and safety is called biosimilar. Patent and copyright expiration of biological products permits the entry of biosimilars.
Saravanan Bhojaraj, Thirumoorthy Durai Ananda Kumar, Abhinav Raj Ghosh, BS Sushmitha, Srinivasan Ramamurthy, Thirunavukkarasu Velusamy, Thiyagarajan Ramesh, MK Jayanthi, Musthafa Mohammed Essa, Saravana Babu Chidambaram, M. Walid Qoronfleh   +10 more
openaire   +2 more sources

Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.

Inflammatory Bowel Diseases, 2022
BACKGROUND Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for the treatment of a greater number of patients for their reduced cost than the originator.
A. Tursi, G. Mocci, L. Allegretta, G. Aragona, M. Bianco, R. Colucci, A. Cuomo, N. della Valle, A. Ferronato, G. Forti, F. Gaiani, G. Giorgetti, M. Graziani, K. Lofano, R. Lorenzetti, T. Larussa, A. Penna, R. Pica, G. Pranzo, S. Rodino, A. Scarcelli, C. Zampaletta, G. Bassotti, A. Cazzato, S. Chiri, V. Clemente, A. Cocco, Gianluigi De’ Angelis, L. Donnarumma, R. Faggiani, Camilla Graziosi, M. Le Grazie, F. Luzza, C. Meucci, R. Monterubbianesi, C. Pagnini, P. Perazzo, M. Picchio, R. Sacco, L. Sebkova, M. Serio, D. Napolitano, D. Pugliese, F. Scaldaferri, E. Schiavoni, L. Turchini, A. Armuzzi, W. Elisei, G. Maconi, A. Papa   +49 more
semanticscholar   +1 more source

Biosimilar medicines

European Journal of Hospital Pharmacy, 2019
Biological medicines have become indispensable in the treatment of patients with serious diseases such as cancer and inflammatory diseases. Biosimilars are medicines which are developed to be similar to existing biological medicines (the 'reference product'). For the European market, they are approved by the European Medicines Agency.
András Süle, Frank Jørgensen, Petr Horák, Joan Peppard, Stephanie Kohl   +4 more
openaire   +2 more sources

Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems

Clinical and Experimental Medicine (Testo stampato)
Inflammatory bowel disease (IBD) is a multifactorial illness with a climbing prevalence worldwide. While biologics are commonly prescribed especially for severe cases, they may worsen patients’ outcomes due to financial burden.
Ahmad M Aljabri, G. M. Soliman, Y. N. Ramadan, M. Medhat, H. Hetta   +4 more
semanticscholar   +1 more source

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?

Dermatologic Therapy, 2022
In the last years, adalimumab biosimilars have represented a commonly used alternative to the originator agent in the treatment of moderate to severe hidradenitis suppurativa.
G. Roccuzzo, G. Rozzo, L. Burzi, Federica Repetto, P. Dapavo, S. Ribero, P. Quaglino   +6 more
semanticscholar   +1 more source